BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golán I, Rodríguez de la Fuente L, Costoya JA. NK Cell-Based Glioblastoma Immunotherapy. Cancers (Basel) 2018;10:E522. [PMID: 30567306 DOI: 10.3390/cancers10120522] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Schwalb AM, Srinivasan ES, Fecci PE. Commentary: Laser Interstitial Thermal Therapy for First-Line Treatment of Surgically Accessible Recurrent Glioblastoma: Outcomes Compared With a Surgical Cohort. Neurosurgery 2022;91:e160-e163. [DOI: 10.1227/neu.0000000000002184] [Reference Citation Analysis]
2 Aggarwal P, Luo W, Pehlivan KC, Hoang H, Rajappa P, Cripe TP, Cassady KA, Lee DA, Cairo MS. Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1038096] [Reference Citation Analysis]
3 Hosseinalizadeh H, Habibi Roudkenar M, Mohammadi Roushandeh A, Kuwahara Y, Tomita K, Sato T. Natural killer cell immunotherapy in glioblastoma. Discov Oncol 2022;13:113. [PMID: 36305981 DOI: 10.1007/s12672-022-00567-1] [Reference Citation Analysis]
4 Ghosh M, Lenkiewicz AM, Kaminska B. The Interplay of Tumor Vessels and Immune Cells Affects Immunotherapy of Glioblastoma. Biomedicines 2022;10:2292. [DOI: 10.3390/biomedicines10092292] [Reference Citation Analysis]
5 Giotta Lucifero A, Luzzi S. Emerging immune-based technologies for high-grade gliomas. Expert Rev Anticancer Ther 2022. [PMID: 35924820 DOI: 10.1080/14737140.2022.2110072] [Reference Citation Analysis]
6 Zhao Y, Liu T, Zhou M. Immune-Cell-Derived Exosomes for Cancer Therapy. Mol Pharm 2022. [PMID: 35876318 DOI: 10.1021/acs.molpharmaceut.2c00407] [Reference Citation Analysis]
7 Zhang P, Liu G, Hu J, Chen S, Wang B, Peng P, Yu X, Guo D. Tenascin-C can Serve as an Indicator for the Immunosuppressive Microenvironment of Diffuse Low-Grade Gliomas. Front Immunol 2022;13:824586. [PMID: 35371015 DOI: 10.3389/fimmu.2022.824586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Codrici E, Popescu ID, Tanase C, Enciu AM. Friends with Benefits: Chemokines, Glioblastoma-Associated Microglia/Macrophages, and Tumor Microenvironment. Int J Mol Sci 2022;23:2509. [PMID: 35269652 DOI: 10.3390/ijms23052509] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
9 Balatsoukas A, Rossignoli F, Shah K. NK cells in the brain: implications for brain tumor development and therapy. Trends in Molecular Medicine 2022. [DOI: 10.1016/j.molmed.2021.12.008] [Reference Citation Analysis]
10 Malliou A, Kyritsis AP, Alexiou GA. Immunotherapeutic Strategies for Glioma Treatment. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_71] [Reference Citation Analysis]
11 Abadi B, Yazdanpanah N, Nokhodchi A, Rezaei N. Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives. Adv Drug Deliv Rev 2021;179:114035. [PMID: 34740765 DOI: 10.1016/j.addr.2021.114035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
12 Pan C, Zhai Y, Li G, Jiang T, Zhang W. NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. Front Oncol 2021;11:751183. [PMID: 34765554 DOI: 10.3389/fonc.2021.751183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Persano S, Vicini F, Poggi A, Fernandez JLC, Rizzo GMR, Gavilán H, Silvestri N, Pellegrino T. Elucidating the Innate Immunological Effects of Mild Magnetic Hyperthermia on U87 Human Glioblastoma Cells: An In Vitro Study. Pharmaceutics 2021;13:1668. [PMID: 34683961 DOI: 10.3390/pharmaceutics13101668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
14 Mormino A, Cocozza G, Fontemaggi G, Valente S, Esposito V, Santoro A, Bernardini G, Santoni A, Fazi F, Mai A, Limatola C, Garofalo S. Histone-deacetylase 8 drives the immune response and the growth of glioma. Glia 2021;69:2682-98. [PMID: 34310727 DOI: 10.1002/glia.24065] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
15 Marofi F, Al-Awad AS, Sulaiman Rahman H, Markov A, Abdelbasset WK, Ivanovna Enina Y, Mahmoodi M, Hassanzadeh A, Yazdanifar M, Stanley Chartrand M, Jarahian M. CAR-NK Cell: A New Paradigm in Tumor Immunotherapy. Front Oncol 2021;11:673276. [PMID: 34178661 DOI: 10.3389/fonc.2021.673276] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 29.0] [Reference Citation Analysis]
16 Lah Turnšek T, Jiao X, Novak M, Jammula S, Cicero G, Ashton AW, Joyce D, Pestell RG. An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5. Int J Mol Sci 2021;22:4464. [PMID: 33923334 DOI: 10.3390/ijms22094464] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Giotta Lucifero A, Luzzi S. Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I). Brain Sci 2021;11:386. [PMID: 33803885 DOI: 10.3390/brainsci11030386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
18 Biserova K, Jakovlevs A, Uljanovs R, Strumfa I. Cancer Stem Cells: Significance in Origin, Pathogenesis and Treatment of Glioblastoma. Cells 2021;10:621. [PMID: 33799798 DOI: 10.3390/cells10030621] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 25.0] [Reference Citation Analysis]
19 Kang YT, Niu Z, Hadlock T, Purcell E, Lo TW, Zeinali M, Owen S, Keshamouni VG, Reddy R, Ramnath N, Nagrath S. On-Chip Biogenesis of Circulating NK Cell-Derived Exosomes in Non-Small Cell Lung Cancer Exhibits Antitumoral Activity. Adv Sci (Weinh) 2021;8:2003747. [PMID: 33747745 DOI: 10.1002/advs.202003747] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 20.0] [Reference Citation Analysis]
20 Majc B, Novak M, Kopitar-Jerala N, Jewett A, Breznik B. Immunotherapy of Glioblastoma: Current Strategies and Challenges in Tumor Model Development. Cells 2021;10:265. [PMID: 33572835 DOI: 10.3390/cells10020265] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 34.0] [Reference Citation Analysis]
21 Piranlioglu R, Bradford JW, Arbab AS. Targeting tumor microenvironment-associated cells to reverse therapy resistance. New Targeting in the Reversal of Resistant Glioblastomas 2021. [DOI: 10.1016/b978-0-12-822527-1.00006-x] [Reference Citation Analysis]
22 Tian Y, Ke YQ, Ma Y. Immune-Related lncRNA Correlated with Transcription Factors Provide Strong Prognostic Prediction in Gliomas. J Oncol 2020;2020:2319194. [PMID: 33178271 DOI: 10.1155/2020/2319194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
23 Kang X, Zheng Y, Hong W, Chen X, Li H, Huang B, Huang Z, Tang H, Geng W. Recent Advances in Immune Cell Therapy for Glioblastoma. Front Immunol 2020;11:544563. [PMID: 33193310 DOI: 10.3389/fimmu.2020.544563] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
24 Huang S, Song Z, Zhang T, He X, Huang K, Zhang Q, Shen J, Pan J. Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas. Front Immunol 2020;11:585034. [PMID: 33193404 DOI: 10.3389/fimmu.2020.585034] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
25 Yalcin F, Dzaye O, Xia S. Tenascin-C Function in Glioma: Immunomodulation and Beyond. Adv Exp Med Biol 2020;1272:149-72. [PMID: 32845507 DOI: 10.1007/978-3-030-48457-6_9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 4.5] [Reference Citation Analysis]
26 Morandi F, Yazdanifar M, Cocco C, Bertaina A, Airoldi I. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells. Cells 2020;9:E1757. [PMID: 32707982 DOI: 10.3390/cells9081757] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 14.5] [Reference Citation Analysis]
27 Luzzi S, Giotta Lucifero A, Brambilla I, Magistrali M, Mosconi M, Savasta S, Foiadelli T. Adoptive immunotherapies in neuro-oncology: classification, recent advances, and translational challenges. Acta Biomed 2020;91:18-31. [PMID: 32608373 DOI: 10.23750/abm.v91i7-S.9952] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
28 Shu C, Li Q. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma. Crit Rev Oncol Hematol 2020;151:102965. [PMID: 32442903 DOI: 10.1016/j.critrevonc.2020.102965] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
29 Tang G, Yin W. Development of an Immune Infiltration-Related Prognostic Scoring System Based on the Genomic Landscape Analysis of Glioblastoma Multiforme. Front Oncol 2020;10:154. [PMID: 32133292 DOI: 10.3389/fonc.2020.00154] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
30 Burger MC, Zhang C, Harter PN, Romanski A, Strassheimer F, Senft C, Tonn T, Steinbach JP, Wels WS. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. Front Immunol 2019;10:2683. [PMID: 31798595 DOI: 10.3389/fimmu.2019.02683] [Cited by in Crossref: 96] [Cited by in F6Publishing: 101] [Article Influence: 32.0] [Reference Citation Analysis]